Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors
Frank Vinluan / medcitynews - Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance. The post El…
AI Summary: Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million, adding small‑molecule oncology assets to its pipeline. The deal accelerates Lilly’s tumor‑targeting strategy, reflects Big Pharma’s preference for buying nimble biotech innovation, and highlights ongoing consolidation trends that determine where promising oncology programs ultimately end up.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
Gilead acquires Tubulis in multibillion-dollar push beyond HIV / 7 wks
Novartis pays $2B for Synnovation’s next‑gen PI3Kα inhibitor / 2 months
Eli Lilly buys Centessa for $6.3B to enter sleep disorder market / 2 months
Merck to acquire Terns Therapeutics for $6.7B / 2 months
Biogen announces $5.6B acquisition of Apellis Pharma / 1 month
Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pharmaceuticals, Clinical Trials, Healthcare Finance, Medicaid and look for the RSS link.
StackHealth Time Machine